I
ImmuneOnco Biopharma
Biotech & Life Sciences · Huangpu, China · Founded 2015 · IPO 2023
Dedicated to the development and commercialization of novel cancer immunotherapy products designed to reverse cancer cell-induced immune inhibition and to actively eradicate cancer cells MoreLess
ImmuneOnco Biopharma, founded in June 2015 in Zhangjiang High Tech Park of Shanghai, China, is an early-stage biotechnology company focused on developing innovative therapies for cancer and viral infections. The company leverages advanced platforms that utilize two types of innate immune cells to achieve its therapeutic goals.
ImmuneOnco operates in the biopharmaceutical market, serving clients such as healthcare providers, research institutions, and pharmaceutical companies. Its business model revolves around the research and development of novel biological medicines, with a particular emphasis on natural killer (NK) cells, which are crucial for the body's defense against diseases. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary therapies.
Keywords: biopharma, cancer therapy, viral infections, innate immune cells, NK cells, biotechnology, Shanghai, early-stage, biological medicines, research and development.
Company overview
ImmuneOnco Biopharma company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2015
- Headquarters
- Huangpu, China
- Employees
- —
- Open positions
- 26
- Dealroom signal
- 59.8
Valuation & funding
ImmuneOnco Biopharma funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Oct 2025 | $42M | — | Undisclosed | ↗ |
| IPOOther financing | Sep 2023 | $30M | $30M | Undisclosed | ↗ |
| SERIES COther financing | Jan 2022 | $100M | $400M | Sunshine Insurance Group Co · CCB Trust · Guoke Jiahe (Beijing) Investment Management · Lilly Asia Ventures | ↗ |
| SERIES COther financing | Mar 2021 | $89M | $356M | Lilly Asia Ventures · Greater Bay Area Homeland Investments | — |
| SERIES BOther financing | Oct 2020 | $25M | $100M | Lilly Asia Ventures | — |
| SERIES BOther financing | Feb 2020 | Undisclosed | ↗ | ||
| SERIES AOther financing | Apr 2018 | Langsheng Investment · Lapam Capital | — | ||
| SERIES AOther financing | Dec 2017 | Undisclosed | — | ||
| ANGELOther financing | Apr 2016 | Zhangjiang Science and Technology Investment | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $21M | 0% | −$27M | -129.2% |
| 2025 | $21M | +108.1% | −$27M | -129.2% |
| 2024 | $10M | +19109.6% | −$38M | -376.6% |
| 2023 | $53K | -28.3% | −$46M | -85786.8% |
| 2022 | $74K | -89.4% | −$53M | -71466.5% |
| 2021 | $697K | — | −$99M | -14233.3% |
Growth signals
ImmuneOnco Biopharma website traffic
Latest recorded traffic for ImmuneOnco Biopharma is 2K monthly website visits, down 16.7% over the last three months.
Hiring
Open positions at ImmuneOnco Biopharma
Current openings linked to this company in Dealroom.
Comparisons
ImmuneOnco Biopharma compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
ImmuneOnco Biopharma's talent
Source: Dealroom Talent Intelligence.
Investors
11 investors on ImmuneOnco Biopharma's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where ImmuneOnco Biopharma has talent and traffic
In the news
Latest news about ImmuneOnco Biopharma
Recent press, funding announcements, and product moves mentioning ImmuneOnco Biopharma — open to read from the original sources.
Market sentiment
What the market is saying about ImmuneOnco Biopharma
An AI-synthesized read of the highest-engagement posts about ImmuneOnco Biopharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ImmuneOnco Biopharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.